Amgen (NASDAQ:AMGN), a United States-based biopharmaceutical company, announced on Thursday that it has completed its acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company.
The transaction is valued at USD52 per share in cash, representing aggregate merger consideration of around USD3.7bn.
The deal includes TAVNEOS, an orally administered selective complement 5a receptor inhibitor that received approval from the US Food and Drug Administration as an adjunctive therapy for adults with severe active ANCA-associated vasculitis in addition to standard of care that includes glucocorticoids and either rituximab or cyclophosphamide immunosuppressant therapy. It also adds three early-stage drug candidates that are aimed at chemoattractant receptors and other inflammatory diseases and an oral checkpoint for cancer.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007